Improving glycaemic control with current therapies

Diabetic Medicine

Volumn 15, Issue SUPPL. 4, 1998, Pages

  Birkeland, Kåre I ^a  

^a AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

Diet; Glycaemic control; Insulin; Oral hypoglycaemic agents; Physical activity; Therapy; Type 2 diabetes mellitus

Indexed keywords

INSULIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

BLOOD GLUCOSE MONITORING; DIABETES CONTROL; DIET THERAPY; DISEASE COURSE; GLUCOSE BLOOD LEVEL; HOME MONITORING; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PATIENT COUNSELING; PHYSICAL ACTIVITY; QUALITY OF LIFE; REVIEW;

BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; LIFE STYLE; QUALITY OF LIFE; RISK FACTORS;

EID: 0031767936     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1096-9136(1998120)15:4+3.3.co;2-e     Document Type: Article

References (40)

1. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995; 18: 258-268.
2. Uusitupa MIJ, Niskanan LK, Siitonen O, Voutilainen E, Pyörälä K. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia 1993; 36: 1175-1184.
3. Andersson DKG, Svardskudd K. Long-term glycemic control relates to mortality in type 2 diabetes. Diabetes Care 1995; 18: 1534-1543.
4. Kuusisto J, Mykkänen L, Pyörälä K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994; 43: 960-967.
5. Gall M-A, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving HH. Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 1995; 44: 1303-1309.
6. Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes. Stroke 1996; 27: 63-68.
7. Ohkubo Y, Kishikawa K, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diab Res Clin Pract 1995; 28: 103-117.
8. Malmberg K, Rydén L, Efendic S, Herlitz J, Nicol P, Waldenström A, Wedel H, Welin L. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI Study): Effects on mortality at 1 year. J Am Coll Cardiol 1995; 26: 57-65.
9. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
10. Claudi T, Cooper J, Skogøy K, Fjelde Hausken M, Melbye H. Diabetesomsorg i norsk allmennpraksis - En tilstandsrapport fra Salten og deler av Rogaland. Tidsskr Nor Lœgeforen 1997; 117: 3661-3664.
11. Clauson P, Linnarsson R, Gottsäter A, Sundkvist G, Grill V. Relationships between diabetes duration, metabolic control and β-cell function in a representative population of type 2 diabetic patients in Sweden. Diabet Med 1994; 11: 794-801.
12. Groop L, Schalin C, Franssila-Kallunki A, Widen, Ekstrand A, Eriksson J. Characteristics of non-insulin-dependent diabetic patients with secondary failure to oral antidiabetic therapy. Am J Med 1989; 87: 183-190.
13. Birkeland KI, Rishaug U, Hanssen KF, Vaaler S. NIDDM: A rapid progressive disease. Results from a long-term, randomised, comparative study of insulin or sulphonylurea treatment. Diabetologia 1996; 39: 1629-1633.
14. Turner R, Cull C, Holman R. UKPDS 17: The effect of improved metabolic control on complications in NIDDM. Ann Intern Med 1996; 124: 136-145.
15. Yki-Järvinen H. Pathogenesis of non-insulin-dependent diabetes mellitus. Lancet 1994; 343: 91-95.
16. Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, Shattock M, Bottazzo GF, Holman R. UKPDS 25: Autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet 1997; 350: 1288-1293.
17. Groop L, Miettinen A, Groop P-H, Meri S, Koskimies S, Bottazzo GF. Organ specific autoimmunity and HLA-DR antigens as markers for beta cell destruction in patients with type 2 diabetes. Diabetes 1988; 37: 99-103.
18. Lehto M, Tuomi T, Mahtani MM, Widén E, Forsblom C, Sarelin L, et al. Characterization of the MODY3 phenotype. Early-onset diabetes caused by an insulin secretion defect. J Clin Invest 1997; 99: 582-591.
19. Ha T, Lean MEJ. Diet and lifestyle modification in the management of non-insulin-dependent diabetes mellitus. In: Textbook of Diabetes. 2nd ed. Pickup J, Williams G (eds). Oxford: Blackwell Science, 1997.
20. United Kingdom Prospective Diabetes Study (UKPDS) 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995; 310: 83-88.
21. Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HPF, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352: 167-173.
22. Hollander P. The role of orlistat in the treatment of obese patients with Type 2 diabetes. Abstracts from a satellite symposium to the 16th International Diabetes Federation Congress, Helsinki, 1997, 'How to improve the management of obese diabetic patients'.
23. Yudkin JS. How can we best prolong life? Benefits or coronary risk factor reduction in non-diabetic and diabetic subjects. BMJ 1993; 306: 1313-1318.
24. Torjesen PA, Birkeland KI, Anderssen SA, Hjermann I, Holme I, Urdal P. Lifestyle changes may reverse development of the insulin resistance syndrome. Diabetes Care 1997; 20: 26-31.
25. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet 1998; 854-865
26. Hermann LS, Schersten B, Bitzen P-O, Kjellström T, Lingärde F, Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1994; 17: 1100-1109.
27. Abbasi F, Kamath V, Rizvi AA, Carantoni M, Chen YD, Reaven GM. Results of a placebo-controlled study of the metabolic effects of the addition of metformin to sulfonylurea-treated patients. Evidence for a central role of adipose tissue. Diabetes Care 1997; 20: 1863-1869.
28. Bayraktar M, Van Thiel DH, Adalar N. A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients. Diabetes Care 1996; 19: 252-254.
29. Lindström TH, Arnqvist HJ, von Schenck HH. Effects of conventional and intensified insulin therapy on free-insulin profiles and glycemic control in NIDDM. Diabetes Care 1992; 15: 27-34.
30. Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Johnson NN, Comstock JP, Emanuele NV, et al. for the VA CSDM Group. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). Diabetes Care 1995; 18: 1113-1123.
31. Clauson PG, Linde B. Absorption of rapid-acting insulin in obese and nonobese NIDDM patients. Diabetes Care 1995; 18: 986-991.
32. Anderson HJ, Brunelle RL, Keohane P, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Arch Intern Med 1997; 157: 1249-1255.
33. Stout RW. Insulin and atheroma - An update. Lancet 1987; i: 1077-1079.
34. Schwartz CJ, Valente AJ, Sprague EA, Kelley JL, Cayatte AJ, Rozek MM. Pathogenesis of the atherosclerotic lesion: Implications for diabetes mellitus. Diabetes Care 1992; 15: 1156-1167.
35. Pugh JA, Ramirez G, Wagner ML, Tuley M, Sawyer J, Friedber SJ. Is sulfonylurea and insulin therapy useful in NIDDM patients? Diabetes Care 1992; 15: 953-959.
36. Peters AL, Davidson MB. Insulin plus a sulfonylurea agent for treating type 2 diabetes. Ann Intern Med 1991; 115: 45-53.
37. Yki-Järvinen H, Nikkilä K, Ryysy L, Tulokas T, Vanamo R Heikkilä M. New thoughts of insulin therapy in NIDDM. 16th International Diabetes Federation Congress, Helsinki, Finland 1997. Abstracts for the State-of-the-Art Lectures and Symposias p4.
38. Coniff RF, Shapiro JA, Seaton TB, Hoogwerf BJ, Hunt JA. A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type 2 diabetes. Diabetes Care 1995; 18: 928-932.
39. Patrick AV, Gill GV, MacFarlane IA, Cullen A, Power E, Wallymahmed M. Home glucose monitoring in type 2 diabetes: Is it a waste of time? Diabet Med 1994; 11: 62-65.
40. Garancini MP, Gallus G, Cucinotta D, Rossi A, Riccardi G, STEMTIC Group. Factors related to glycemic control on IDDM and insulin-treated NIDDM patients in current Practice. Diabetes Care 1997; 20: 1659-1663.